SCYNEXIS spent the first half of the year converting a stalled antifungal partnership into a rare-kidney story. The company bought an AMP-activated protein kinase activator from Poxel, financed the deal with a spring private placement, and recast itself as a developer for autosomal dominant polycystic kidney disease. That is a real strategic change, not a label swap. The market is still treating the equity as leftover cash plus a low-probability option, which is why the shares close below the cash pile even after the reverse split restored the Nasdaq listing.
The accounting profit in the June quarter is not the operating story. Reported net income came from a large noncash warrant revaluation as the share price fell, while license revenue from the GSK ibrexafungerp arrangement shrank to a residual trickle. Cash, cash equivalents, and investments stood at seventy-one million at mid-year after the placement closed. That balance funds a Phase one food-effect and pharmacokinetics study already under way, a planned Phase two proof-of-concept start later this year, and a next-generation antifungal that management is shopping for outside capital. The strongest argument against the setup is that SCY-770 has never shown human efficacy in polycystic kidney disease; prior work was in fatty-liver volunteers.
The next several months resolve whether the pivot is a funded clinical program or a cash box waiting for another reset. Clean Phase one data and an on-time Phase two start would support the cash-backed option. A delay, a noisy safety signal, or continued silence on the GSK relaunch of BREXAFEMME would keep the equity pinned to a discount to cash. The open question is whether the market is underpaying for a financed rare-disease shot, or correctly refusing to capitalize a molecule that still has to prove it belongs in the kidney.